Zacks: Akcea Therapeutics, Inc. (AKCA) Receives Consensus Recommendation of “Strong Buy” from Brokerages
Shares of Akcea Therapeutics, Inc. (NASDAQ:AKCA) have been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price objective of $24.00 for the company, according to Zacks. Zacks has also given Akcea Therapeutics an industry rank of 109 out of 265 based on the ratings given to its competitors.
A number of research analysts have commented on the company. Stifel Nicolaus assumed coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued a “buy” rating and a $19.00 price objective on the stock. BMO Capital Markets started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $25.00 price objective on the stock. Wells Fargo & Company started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $27.00 price target on the stock. Cowen Inc started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded Akcea Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th.
Akcea Therapeutics (NASDAQ AKCA) opened at $18.69 on Friday. Akcea Therapeutics has a 12-month low of $8.10 and a 12-month high of $31.23.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.